Healthcare Sales & Marketing Network News: levocetirizine dihydrochloride

Searching News Database: levocetirizine dihydrochloride

HSMN NewsFeed - 24 Aug 2009
FDA Approves XYZAL(R) For Use In Children Age Six Months And Older For The Relief Of Perennial Allergic Rhinitis And Chronic Idiopathic Urticaria
Biopharmaceuticals FDA

HSMN NewsFeed - 19 Feb 2008
FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
Biopharmaceuticals FDA

HSMN NewsFeed - 29 May 2007
FDA Approves XYZAL(R) (Levocetirizine Dihydrochloride) Tablets for the Relief of Seasonal and Year Round Allergies, and Chronic Hives
Biopharmaceuticals FDA

HSMN NewsFeed - 25 Sep 2006
sanofi-aventis and UCB Sign a Co-Promotion Agreement for Xyzal(R) in the United States
Biopharmaceuticals

HSMN NewsFeed - 25 Sep 2006
UCB and sanofi-aventis sign a co-promotion agreement for Xyzal(R) in the United States
Biopharmaceuticals

Return to NewsFeed

Additional items found! 1

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 1 additional stories matching:
levocetirizine dihydrochloride
(Password required)

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.